MPN-149: Long-Term Safety of Momelotinib in JAK Inhibitor-Naïve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients

骨髓纤维化 鲁索利替尼 医学 内科学 贫血 随机对照试验 胃肠病学 骨髓
作者
Claire Harrison,Björn Andréasson,Nathalie Cambier,Aaron T. Gerds,Sebastian Grosicki,Árpád Illés,Jean‐Jacques Kiladjian,David Lavie,Ruben A. Mesa,Jeanne Palmer,Francesco Passamonti,Andrew Perkins,Tomasz Sacha,Christof Scheid,Doroteya K. Todorieva-Todorova,Alessandro M. Vannucchi,T Woźny,Barbara Klencke,Mark Kowalski,Srđan Verstovšek
出处
期刊:Clinical Lymphoma, Myeloma & Leukemia [Elsevier]
卷期号:20: S330-S331
标识
DOI:10.1016/s2152-2650(20)30993-9
摘要

Background: Momelotinib (MMB) is a potent, orally bioavailable, small-molecule inhibitor of JAK1, JAK2, and ACVR1 with demonstrable clinical activity against the three hallmark features of myelofibrosis (MF), namely anemia, constitutional symptoms, and splenomegaly, across the continuum of intermediate-/high-risk MF patients whether JAKi-naïve or previously JAKi-treated. Objective: To characterize the long-term safety of MMB in comparison to ruxolitinib (RUX). Methods: SIMPLIFY-1 was a double-blind, randomized, study of MMB vs RUX in intermediate-/high-risk JAKi-naïve patients with MF (n=215 MMB, 217 RUX). SIMPLIFY-2 (S2) was a randomized study of MMB vs best available therapy (BAT; RUX in 88% of patients) in prior RUX-treated patients with hematological toxicity (n=104 MMB, 52 BAT). Randomized treatment (RT) for 24 weeks was followed by open-label MMB extended treatment in both studies. Data from RT were compared, and further long-term data were analyzed from 550 subjects receiving MMB, including 336 subjects on MMB for ≥48 weeks and 148 for ≥144 weeks. Results: Despite treatment duration exceeding 3.5 years for >90 subjects, the incidence of grade 3/4 hematological toxicity was very low. During the S1 RT period, grade 3/4 anemia occurred in only 6.1% of MMB subjects compared with -4-fold higher rate (22.7%) for RUX. Dose reductions due to thrombocytopenia were also 4-fold higher for RUX (24.5%) than MMB (6.1%). Subjects randomized to MMB in S1 experienced a rapid, sustained increase in hemoglobin, in contrast to significant hemoglobin decrease on RUX. Following crossover to MMB from RUX, hemoglobin increased rapidly to above baseline. Platelet values were also significantly higher compared to RUX. Similarly, in S2, hemoglobin and platelet values were maintained or improved on MMB. Importantly, no new safety signals and no cumulative toxicity were observed during extended MMB dosing. Rates of peripheral neuropathy remained low. Conclusions: MMB displays very favorable long-term tolerability, including an absence of significant rates of high-grade hematological and other toxicities or evidence of cumulative toxicity, consistent with its differentiated pharmacological and clinical profile. Notably, subjects switching from RUX also experienced favorable tolerability, despite their previous therapy. Momelotinib (MMB) is a potent, orally bioavailable, small-molecule inhibitor of JAK1, JAK2, and ACVR1 with demonstrable clinical activity against the three hallmark features of myelofibrosis (MF), namely anemia, constitutional symptoms, and splenomegaly, across the continuum of intermediate-/high-risk MF patients whether JAKi-naïve or previously JAKi-treated. To characterize the long-term safety of MMB in comparison to ruxolitinib (RUX). SIMPLIFY-1 was a double-blind, randomized, study of MMB vs RUX in intermediate-/high-risk JAKi-naïve patients with MF (n=215 MMB, 217 RUX). SIMPLIFY-2 (S2) was a randomized study of MMB vs best available therapy (BAT; RUX in 88% of patients) in prior RUX-treated patients with hematological toxicity (n=104 MMB, 52 BAT). Randomized treatment (RT) for 24 weeks was followed by open-label MMB extended treatment in both studies. Data from RT were compared, and further long-term data were analyzed from 550 subjects receiving MMB, including 336 subjects on MMB for ≥48 weeks and 148 for ≥144 weeks. Despite treatment duration exceeding 3.5 years for >90 subjects, the incidence of grade 3/4 hematological toxicity was very low. During the S1 RT period, grade 3/4 anemia occurred in only 6.1% of MMB subjects compared with -4-fold higher rate (22.7%) for RUX. Dose reductions due to thrombocytopenia were also 4-fold higher for RUX (24.5%) than MMB (6.1%). Subjects randomized to MMB in S1 experienced a rapid, sustained increase in hemoglobin, in contrast to significant hemoglobin decrease on RUX. Following crossover to MMB from RUX, hemoglobin increased rapidly to above baseline. Platelet values were also significantly higher compared to RUX. Similarly, in S2, hemoglobin and platelet values were maintained or improved on MMB. Importantly, no new safety signals and no cumulative toxicity were observed during extended MMB dosing. Rates of peripheral neuropathy remained low. MMB displays very favorable long-term tolerability, including an absence of significant rates of high-grade hematological and other toxicities or evidence of cumulative toxicity, consistent with its differentiated pharmacological and clinical profile. Notably, subjects switching from RUX also experienced favorable tolerability, despite their previous therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhdjj完成签到 ,获得积分10
11秒前
sydhwo完成签到 ,获得积分10
13秒前
无极2023完成签到 ,获得积分10
18秒前
特别圆的正方形完成签到 ,获得积分10
19秒前
iShine完成签到 ,获得积分10
26秒前
会发芽完成签到 ,获得积分10
27秒前
CC2333完成签到 ,获得积分10
30秒前
卓矢完成签到 ,获得积分10
30秒前
jue完成签到 ,获得积分10
33秒前
GuangboXia完成签到,获得积分10
33秒前
研友_LN32Mn完成签到,获得积分10
41秒前
yinhe完成签到 ,获得积分10
44秒前
Singularity应助科研通管家采纳,获得10
47秒前
天天快乐应助科研通管家采纳,获得10
47秒前
Singularity应助科研通管家采纳,获得10
47秒前
传奇3应助科研通管家采纳,获得10
47秒前
范白容完成签到 ,获得积分10
48秒前
但大图完成签到 ,获得积分10
52秒前
启程牛牛完成签到,获得积分0
55秒前
侠医2012完成签到,获得积分10
56秒前
九天完成签到 ,获得积分10
59秒前
酱豆豆完成签到 ,获得积分10
1分钟前
dent强完成签到 ,获得积分10
1分钟前
Xx完成签到 ,获得积分10
1分钟前
玩命的无春完成签到 ,获得积分10
1分钟前
Bill Wang完成签到 ,获得积分10
1分钟前
大气夜山完成签到 ,获得积分10
1分钟前
邵翎365完成签到,获得积分10
1分钟前
Enchanted完成签到 ,获得积分10
1分钟前
starwan完成签到 ,获得积分10
1分钟前
绿色催化完成签到,获得积分20
1分钟前
woshiwuziq完成签到 ,获得积分10
1分钟前
丹丹完成签到,获得积分10
1分钟前
Jack80发布了新的文献求助50
1分钟前
Heidi完成签到 ,获得积分10
2分钟前
小绵羊完成签到 ,获得积分10
2分钟前
天行健完成签到,获得积分10
2分钟前
科研通AI2S应助孤巷的猫采纳,获得10
2分钟前
Summer_Xia完成签到,获得积分10
2分钟前
青黛完成签到 ,获得积分10
2分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709874
关于积分的说明 7418267
捐赠科研通 2354446
什么是DOI,文献DOI怎么找? 1246020
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921